Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xeris Biopharma Holdings, Inc. - Common Stock
(NQ:
XERS
)
7.565
-0.055 (-0.72%)
Streaming Delayed Price
Updated: 9:36 AM EST, Jan 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xeris Biopharma Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022
November 02, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology
November 01, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
10 Best Medical Stocks Under $5
↗
October 29, 2022
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the...
Via
Talk Markets
Earnings Scheduled For May 11, 2022
↗
May 11, 2022
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Via
Benzinga
Earnings Scheduled For March 10, 2022
↗
March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...
Via
Benzinga
Xeris Biopharma Posts Encouraging Data From Reformulated Thyroid Hormone Deficiency Treatment In Healthy Participants
↗
October 20, 2022
Via
Benzinga
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
October 20, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
August 10, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Earnings Scheduled For August 10, 2022
↗
August 10, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.
Via
Benzinga
121 Stocks That Hit Their 52-Week Low
↗
October 14, 2022
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.
Via
Benzinga
Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
August 03, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
August 01, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
June 16, 2022
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning.
Via
InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
↗
June 16, 2022
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO.
Via
Benzinga
73 Biggest Movers From Yesterday
↗
May 17, 2022
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Via
Benzinga
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
May 12, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
↗
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Xeris Biopharma Holdings: Q1 Earnings Insights
↗
May 11, 2022
Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
May 11, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals's Earnings Outlook
↗
May 10, 2022
Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
May 04, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
↗
April 28, 2022
Via
Benzinga
Analyst Ratings For Xeris Biopharma Holdings
↗
March 16, 2022
Xeris Biopharma Holdings (NASDAQ:XERS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
March 16, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Recap: Xeris Biopharma Holdings Q4 Earnings
↗
March 10, 2022
Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the...
Via
Benzinga
A Preview Of Xeris Pharmaceuticals's Earnings
↗
March 09, 2022
Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....
Via
Benzinga
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Xeris Biopharma Holdings
Via
Business Wire
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
January 31, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
18 Stocks Moving in Monday's Pre-Market Session
↗
January 31, 2022
Gainers FGI Industries Ltd. (NASDAQ: FGI) rose 92.8% to $7.27 in pre-market trading after jumping 19% on Friday. The company, last week, priced its IPO at $6 per...
Via
Benzinga
Xeris Biopharma Eyes High End Of FY21 Sales Outlook
↗
January 18, 2022
Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
